Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 7,796 shares at $130.58 ($1.0M) on 2018-12-10, disclosed to the SEC on 2018-12-12.
Open-market sale of $1.0M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $130.58 | 969 | $127K | 12.1% |
| 2 | $132.09 | 2,001 | $264K | 25.4% |
| 3 | $134.31 | 2,049 | $275K | 26.4% |
| 4 | $135.04 | 2,377 | $321K | 30.8% |
| 5 | $136.48 | 400 | $55K | 5.2% |
| Total | $133.61 avg | 7,796 |
| $1.0M |
| 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $2.7M | — | Filing → |
| LOXO | SELL | 2018-12-12 | $915K | — | Filing → |
| LOXO | SELL | 2018-11-28 | $1.2M | — | Filing → |